Extended-release intramuscular naltrexone: a viewpoint by Steven Siegel.
Siegel
Steven
S
Division of Neuropsychiatry, Department of Psychiatry, University of Pennsylvania, Philadelphia, PA, USA.
D000437:Alcoholism / Q000188:drug therapy*; D003692:Delayed-Action Preparations / Q000008:administration & dosage / Q000627:therapeutic use*; D006801:Humans; D007273:Injections, Intramuscular; D019344:Lactic Acid / Q000737:chemistry; D008863:Microspheres; D009271:Naltrexone / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use*; D009292:Narcotic Antagonists / Q000008:administration & dosage / Q000737:chemistry / Q000627:therapeutic use; D010349:Patient Compliance / Q000706:statistics & numerical data; D011100:Polyglycolic Acid / Q000737:chemistry; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011108:Polymers / Q000737:chemistry; D016896:Treatment Outcome
D003692:Delayed-Action Preparations; D009292:Narcotic Antagonists; D011108:Polymers; D000077182:Polylactic Acid-Polyglycolic Acid Copolymer; D011100:Polyglycolic Acid; D019344:Lactic Acid; D009271:Naltrexone